• TRINITY: A Phase II Clinical Trial in
    Small Cell Lung Cancer


    The study of Rovalpituzumab Tesirine as a third-line or later treatment in patients who have relapsed or refractory small cell lung cancer (SCLC).

  • Learn more about our clinical trial.

    TRINITY is an ongoing clinical trial for people with a certain type of lung cancer called small cell lung cancer (SCLC). It is being conducted to see if rovalpituzumab tesirine, an investigational drug, is safe and effective for the treatment of SCLC that has failed other chemotherapies.

    It is important to note that rovalpituzumab tesirine has not been approved for the treatment of SCLC and its use in SCLC remains investigational. Therefore, all patients should learn as much as possible about the study and fully consider its risks and benefits with their doctor before participating.

  • Who might qualify

    This study may be an option for patients who are:

    • 18 years old or older
    • Have small cell lung cancer that has returned or progressed despite at least two previous regimens of chemotherapy

    To find out more about TRINITY click here.

  • About SCLC

    Learn more about small cell lung cancer

    National Cancer Institute

    PDQ® Small Cell Lung Cancer Treatment

  • Talk to your doctor

    Please discuss your treatment options with your doctor to determine if this study may be a good option for you.  Your doctor can review the study and discuss the potential risks and benefits with you and your family.


    Download and print the TRINITY trial information sheet.

  • Clinical Trial Site Locations

    TRINITY is currently open for enrollment at the following locations:

  • For Healthcare Professionals

    If you are a licensed healthcare professional who would like to learn more about the TRINITY study and/or would like to learn how to refer a patient, please click on the button below.